Bayer to partner on reversing bleeding from Xarelto
FRANKFURT (Reuters) - German drugmaker Bayer said on Tuesday it planned to collaborate with U.S. peer Portola Pharmaceuticals to study several drugs that reverse the effects of its blood-thinner Xarelto.
Bayer said it expected to complete the study in the second half of this year.
Dangerous bleeding is one of the main risks of bloodthinners such as Xarelto, which are used against thrombosis or heart attacks, and drugs can be applied more widely if they have so-called "antidotes".
U.S. regulators last June rejected the use of Xarelto to prevent heart attacks and strokes in patients with acute coronary syndrome (ACS), citing the risk of bleeding.
Bayer said in September its development partner Johnson & Johnson had filed a response to the regulators' concerns.
(Reporting By Peter Dinkloh; Editing by David Cowell)
- 'Weird Al' Yankovic still trying to wrap head around No. 1 album
- World's oldest joke traced back to 1900 BC
- French warplanes search Mali desert for crashed Air Algerie plane |
- Crunch time for Gaza truce talks as death toll passes 800 |
- Wreckage of Air Algerie plane carrying 116 people found in Mali |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video